CAMBRIDGE, Mass., Sept. 25, 2019 – BlueRock Therapeutics, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock and Vice Chairman of the Alliance for Regenerative Medicine (ARM), will present at the Cell & Gene Meeting on the Mesa, to be held Oct. 2-4 […]
CAMBRIDGE, Mass., May 23, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: BIO International Convention Corporate […]
CAMBRIDGE, Mass., April 18, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced its participation in the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 […]
CAMBRIDGE, Mass., March 5, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock Therapeutics, will present at the Cowen and Company […]
CAMBRIDGE, Mass., Jan. 2, 2019 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that Emile Nuwaysir, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare […]
CAMBRIDGE, Mass., Nov. 7, 2018 – BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: American Heart […]
BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced its participation in the Cell & Gene Meeting on the Mesa, to be held Oct. 3-5 in La Jolla, Calif.
